Resolution of bortezomib-associated chalazia/blepharitis after switch to ixazomib: A case report

Curr Res Transl Med. 2021 May;69(2):103283. doi: 10.1016/j.retram.2021.103283. Epub 2021 Feb 24.

Authors

Jean Lemoine¹, Agnes Bonnin¹, Zora Marjanovic¹, Zoe van de Wyngaert¹, Souhila Ikhlef¹, Tamim Alsuliman¹, Fella M'Hammedi-Bouzina¹, Mohamad Mohty¹, Florent Malard²

Affiliations

¹ Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France.
² Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France. Electronic address: florent.malard@inserm.fr.

PMID: 33639586
DOI: 10.1016/j.retram.2021.103283

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Blepharitis*
Boron Compounds / adverse effects
Bortezomib / adverse effects
Chalazion*
Glycine / analogs & derivatives
Humans

Substances

Boron Compounds
Bortezomib
ixazomib
Glycine